IMMUNITYBIO, INC. Fair Value Adjustment of Warrants
IMMUNITYBIO, INC. (IBRX) reported Fair Value Adjustment of Warrants of $44.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2026-08-04
- IMMUNITYBIO, INC. fair value adjustment of warrants for the quarter ending 2026-06-30 was $44.19M.
- IMMUNITYBIO, INC. fair value adjustment of warrants for the quarter ending 2026-03-31 was $295.41M, a 65840.40% increase year-over-year.
- IMMUNITYBIO, INC. fair value adjustment of warrants for the quarter ending 2025-12-31 was -$30.74M.
- IMMUNITYBIO, INC. fair value adjustment of warrants for the quarter ending 2025-09-30 was -$14.90M.
- IMMUNITYBIO, INC. fair value adjustment of warrants for fiscal 2025 was -$49.09M.
- IMMUNITYBIO, INC. fair value adjustment of warrants for fiscal 2024 was -$19.95M, a 141.92% decline from fiscal 2023.
- IMMUNITYBIO, INC. fair value adjustment of warrants for fiscal 2023 was $47.60M.
- IMMUNITYBIO, INC. fair value adjustment of warrants for fiscal 2022 was -$13.46M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2026-06-30 | $44.19M 10-Q · filed 2026-08-04 | $339.60M 10-Q · filed 2026-08-04 | $308.86M derived: sum of 3 quarters · filed 2026-08-04 | $293.95M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $295.41M 10-Q · filed 2026-05-07 | $264.67M derived: sum of 2 quarters · filed 2026-05-07 | $249.76M derived: sum of 3 quarters · filed 2026-05-07 | $245.88M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$30.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$45.65M derived: sum of 2 quarters · filed 2026-02-23 | -$49.54M derived: sum of 3 quarters · filed 2026-08-04 | -$49.09M 10-K · filed 2026-02-23 |
| 2025-09-30 | -$14.90M 10-Q · filed 2025-11-05 | -$18.79M derived: sum of 2 quarters · filed 2026-08-04 | -$18.35M 10-Q · filed 2025-11-05 | -$28.08M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$3.89M 10-Q · filed 2026-08-04 | -$3.44M 10-Q · filed 2026-08-04 | -$13.17M derived: sum of 3 quarters · filed 2026-08-04 | -$44.50M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $448.00K 10-Q · filed 2026-05-07 | -$9.29M derived: sum of 2 quarters · filed 2026-05-07 | -$40.61M derived: sum of 3 quarters · filed 2026-05-07 | -$21.31M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$9.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$41.06M derived: sum of 2 quarters · filed 2026-02-23 | -$21.76M derived: sum of 3 quarters · filed 2026-02-23 | -$19.95M 10-K · filed 2026-02-23 |
| 2024-09-30 | -$31.32M 10-Q · filed 2025-11-05 | -$12.02M derived: sum of 2 quarters · filed 2025-11-05 | -$10.22M 10-Q · filed 2025-11-05 | $69.18M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $19.30M 10-Q · filed 2025-08-05 | $21.10M 10-Q · filed 2025-08-05 | $100.50M derived: sum of 3 quarters · filed 2026-02-23 | $86.24M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $1.80M 10-Q · filed 2025-05-12 | $81.20M derived: sum of 2 quarters · filed 2026-02-23 | $66.94M derived: sum of 3 quarters · filed 2026-02-23 | $76.96M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $79.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $65.14M derived: sum of 2 quarters · filed 2026-02-23 | $75.15M derived: sum of 3 quarters · filed 2026-02-23 | $47.60M 10-K · filed 2026-02-23 |
| 2023-09-30 | -$14.27M 10-Q · filed 2024-11-12 | -$4.25M derived: sum of 2 quarters · filed 2024-11-12 | -$31.80M 10-Q · filed 2024-11-12 | -$45.26M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $10.02M 10-Q · filed 2024-08-12 | -$17.54M 10-Q · filed 2024-08-12 | -$31.00M derived: sum of 3 quarters · filed 2025-03-03 | -$31.00M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | -$27.55M 10-Q · filed 2024-05-09 | -$41.01M derived: sum of 2 quarters · filed 2025-03-03 | -$41.01M derived: sum of 3 quarters · filed 2025-03-03 | -$41.01M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | -$13.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$13.46M derived: sum of 2 quarters · filed 2025-03-03 | -$13.46M derived: sum of 3 quarters · filed 2025-03-03 | -$13.46M 10-K · filed 2025-03-03 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-19 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 | |||
| 2017-12-31 | $0.00 10-K · filed 2018-03-12 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $0.00 derived: sum of 2 quarters · filed 2018-03-12 | $0.00 10-K · filed 2018-03-12 | |
| 2016-09-30 | $0.00 10-Q · filed 2016-11-10 | $0.00 10-Q · filed 2016-11-10 | ||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $0.00 derived: sum of 2 quarters · filed 2018-03-12 | $483.00K derived: sum of 3 quarters · filed 2018-03-12 | $1.37M 10-K · filed 2018-03-12 |
| 2015-09-30 | $0.00 10-Q · filed 2016-11-10 | $483.00K derived: sum of 2 quarters · filed 2016-11-10 | $1.37M 10-Q · filed 2016-11-10 | $1.51M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-06-30 | $483.00K 10-Q · filed 2016-08-15 | $1.37M 10-Q · filed 2016-08-15 | $1.51M derived: sum of 3 quarters · filed 2017-03-15 | $1.51M derived: sum of 4 quarters · filed 2017-03-15 |
| 2015-03-31 | $883.00K 10-Q · filed 2016-05-16 | $1.02M derived: sum of 2 quarters · filed 2017-03-15 | $1.02M derived: sum of 3 quarters · filed 2017-03-15 | $1.02M derived: sum of 4 quarters · filed 2017-03-15 |
| 2014-12-31 | $142.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $141.00K derived: sum of 2 quarters · filed 2017-03-15 | $135.00K derived: sum of 3 quarters · filed 2017-03-15 | $158.00K 10-K · filed 2017-03-15 |
| 2014-09-30 | -$1.00K 10-Q · filed 2015-11-12 | -$7.00K derived: sum of 2 quarters · filed 2015-11-12 | $16.00K 10-Q · filed 2015-11-12 | |
| 2014-06-30 | -$6.00K 10-Q · filed 2015-09-10 | $17.00K 10-Q · filed 2015-09-10 | ||
| 2013-12-31 | -$684.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |